AstraZeneca and Isis announce cancer drug development alliance
AstraZeneca and Isis are working together to bring novel medicines to cancer patients.
AstraZeneca and Isis Pharmaceuticals have entered into a new strategic alliance that will see the companies work together to discover and develop novel anti-cancer therapies.
The alliance will aim to discover novel generation antisense therapies, which target disease-related proteins by destroying the RNA involved in their creation.
Isis' discovery platform develops therapies that bind to messenger RNA to block the production of disease-causing proteins.
AstraZeneca will bring its experience in developing personalised medicines to the strategic alliance, which will develop therapies against five cancer targets, including a license to develop and commercialise Isis' experimental drug candidate, ISIS-STAT3Rx.
"ISIS-STAT3Rx is our first cancer drug to incorporate our new technology and we are encouraged by the early clinical data we have observed," said Dr Brett Monia, senior vice-president of antisense drug discovery at Isis.
"We have worked closely with AstraZeneca to design a rapid path to the market for ISIS-STAT3Rx in these patient populations," he added.
Susan Galbraith, head of AstraZeneca's oncology innovative medicines unit, added that the company's expertise in oncology translational science and the development and commercialisation of oncology products, combined with Isis' innovative approach to discovering novel medicines, "reflect a common goal of bringing new medicines to cancer patients".
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance